CLAIMS

1. A pharmaceutical composition in the form of a gastro-resistant tablet, which pharmaceutical composition is enteric-coated and comprises, based on the total weight of the tablet previous to coating:

(a) 20-30 wt.% of dimethyl fumarate;

(b) 25-35 wt.% of a diluent selected from lactose, D-glucose (dextrose), sucrose, fructose, galactose, calcium carbonate, dibasic calcium phosphate, calcium sulphate, magnesium carbonate, isomalt, mannitol, maltitol, sorbitol, xylitol, and mixtures thereof;

(c) 35-45 wt.% of microcrystalline cellulose;

(d) 1-10 wt.% of croscarmellose sodium; and

wherein the dimethyl fumarate is not covered with a gastro-resistant coating.

2. A pharmaceutical composition according to claim 1 further comprising (e) at least one glidant.

3. A pharmaceutical composition according to claim 2, wherein the glidant (e) is selected from calcium phosphate, calcium silicate, powdered cellulose, magnesium silicate, magnesium trisilicate, silicon dioxide, talc, colloidal silica, colloidal anhydrous silica and mixtures thereof.

4. A pharmaceutical composition according to any one of claims 1 to 3 further comprising (f) at least one lubricant.

5. A pharmaceutical composition according to claim 4, wherein the lubricant (f) is selected from magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulfate, magnesium lauryl sulfate, sodium benzoate, potassium benzoate, light mineral oil, hydrogenated

vegetable oils, glycerin monostearate, glyceryl behenate, glyceryl palmitostearate, stearic acid, zinc stearate, and mixtures thereof.

6. A pharmaceutical composition according to any one of claims 1 to 5 comprising, based on the total weight the tablet previous to coating:

(a) 25 wt.% of dimethyl fumarate;

(b) 30 wt.% of lactose;

(c) 40 wt.% of microcrystalline cellulose;

(d) 4 wt.% of croscarmellose sodium;

(e) 0.5 wt.% of at least one glidant;

(f) 0.5 wt.% at least one lubricant.

7. A pharmaceutical composition as defined in any one of claims 1 to 6 for use in the treatment or prevention of inflammatory or autoimmune diseases or disorders.

8. A pharmaceutical composition according to claim 7, wherein the inflammatory or autoimmune diseases or disorders are selected from rheumatoid arthritis, multiple sclerosis (MS), amyotrophic lateral sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus (SLE), myasthenia gravis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, Sjogren's syndrome, autoimmune hemolytic anemia (AIHA), type I diabetes and psoriasis.

9. Use of a pharmaceutical composition as defined in any one of claims 1 to 6 for the manufacture of a medicament for the treatment or prevention of inflammatory or autoimmune diseases or disorders.

10. Use according to claim 9, wherein the inflammatory or autoimmune diseases or disorders are selected from rheumatoid arthritis, multiple sclerosis

(MS), amyotrophic lateral sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus (SLE), myasthenia gravis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, Sjogren's syndrome, autoimmune hemolytic anemia (AIHA), type I diabetes and psoriasis.